Literature DB >> 23970097

Possible role of dynorphins in Alzheimer's disease and age-related cognitive deficits.

Caroline Ménard1, Herbert Herzog, Christoph Schwarzer, Rémi Quirion.   

Abstract

BACKGROUND/AIMS: Expression of dynorphin, an endogenous opioid peptide, increases with age and has been associated with cognitive deficits in rodents. Elevated dynorphin levels have been reported in postmortem samples from Alzheimer's disease (AD) patients, and prodynorphin (PDYN) gene polymorphisms might be linked to cognitive function in the elderly. Activation of κ-opioid receptors by dynorphins has been associated with stress-related memory impairments. Interestingly, these peptides can also modulate glutamate neurotransmission and may affect synaptic plasticity underlying memory formation. N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazol-propionate (AMPA) ionotropic glutamate receptor levels generally decrease with aging, and their function is impaired in AD.
METHODS: Here, we compared the impact of aging on ionotropic glutamate receptor levels in the hippocampal formation of wild-type (WT) and Pdyn knock-out (KO) mice.
RESULTS: We observed a significant reduction in GluR1 and GluR2 AMPA receptor subunits in the hippocampal formation of 18- to 25-month-old WT mice in comparison with 6-month-old mice. Conversely, the GluR1 protein level was maintained in old Pdyn KO mice, and the NMDA NR2B subunit level was increased by 42% when compared to old WT animals.
CONCLUSIONS: These results suggest that elevated dynorphin expression occurring during aging and AD may mediate cognitive deficits by altering the glutamatergic system integrity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23970097     DOI: 10.1159/000353848

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  8 in total

Review 1.  Opioid modulation of cognitive impairment in depression.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Prog Brain Res       Date:  2018-09-18       Impact factor: 2.453

Review 2.  The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.

Authors:  Martin L Dalefield; Brittany Scouller; Rabia Bibi; Bronwyn M Kivell
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

3.  Maturational alterations in constitutive activity of medial prefrontal cortex kappa-opioid receptors in Wistar rats.

Authors:  Sunil Sirohi; Brendan M Walker
Journal:  J Neurochem       Date:  2015-09-11       Impact factor: 5.372

4.  Glutamatergic signaling and low prodynorphin expression are associated with intact memory and reduced anxiety in rat models of healthy aging.

Authors:  Caroline Ménard; Rémi Quirion; Sylvain Bouchard; Guylaine Ferland; Pierrette Gaudreau
Journal:  Front Aging Neurosci       Date:  2014-05-07       Impact factor: 5.750

5.  Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers.

Authors:  Julia Remnestål; Linn Öijerstedt; Abbe Ullgren; Jennie Olofsson; Sofia Bergström; Kim Kultima; Martin Ingelsson; Lena Kilander; Mathias Uhlén; Anna Månberg; Caroline Graff; Peter Nilsson
Journal:  Transl Neurodegener       Date:  2020-06-23       Impact factor: 8.014

6.  Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer's Disease.

Authors:  How-Wing Leung; Gabriel Foo; Antonius VanDongen
Journal:  Biomedicines       Date:  2022-08-11

7.  Neuroprotective effect of β-asarone against Alzheimer's disease: regulation of synaptic plasticity by increased expression of SYP and GluR1.

Authors:  Si-Jun Liu; Cong Yang; Yue Zhang; Ru-Yu Su; Jun-Li Chen; Meng-Meng Jiao; Hui-Fang Chen; Na Zheng; Si Luo; Yun-Bo Chen; Shi-Jian Quan; Qi Wang
Journal:  Drug Des Devel Ther       Date:  2016-04-15       Impact factor: 4.162

8.  Differences in plasma metabolites related to Alzheimer's disease, APOE ε4 status, and ethnicity.

Authors:  Badri Vardarajan; Vrinda Kalia; Jennifer Manly; Adam Brickman; Dolly Reyes-Dumeyer; Rafael Lantigua; Iuliana Ionita-Laza; Dean P Jones; Gary W Miller; Richard Mayeux
Journal:  Alzheimers Dement (N Y)       Date:  2020-05-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.